As HHS’ Azar Testifies, NACDS Urges His DIR Reform Proposals NACDS’ Congressional statement keys on lowering patients’ costs at pharmacy counter, reducing overall healthcare costs, and fostering pharmacy viability by preventing below-cost reimbursement

2019-03-14T11:16:45+00:00Mar-14-19|Categories: Press Release|Tags: , , , , , |

NACDS’ Congressional statement keys on lowering patients’ costs at pharmacy counter, reducing overall healthcare costs, and fostering pharmacy viability by preventing below-cost reimbursement.

NACDS Urges DIR Fee Reform in Morning Consult Op-Ed NACDS President & CEO Steven C. Anderson emphasizes DIR fee reform’s role in lowering patients’ out of pocket costs, reducing overall healthcare costs

2019-03-08T22:58:39+00:00Mar-08-19|Categories: Press Release|Tags: , , , , , |

Morning Consult today published an opinion piece by the NACDS entitled “DIR Fee Reform: Lining Up Another Win for Patients on Drug Costs.”

NACDS Urges DIR Fee Reform in Statement to House Ways and Means Committee Details opportunities to reduce patients’ out-of-pocket drug costs and to lower overall healthcare spending through DIR fee reform; Describes public’s trust of pharmacies’ cost-saving proposals

2019-02-12T17:07:13+00:00Feb-12-19|Categories: Press Release|Tags: , , , , |

NACDS today submitted a statement to the U.S. House of Representatives Committee on Ways and Means for the hearing titled “The Cost of Rising Prescription Drug Prices.”

NACDS, NCPA Thank Patient, Consumer Groups for Taking Important Stance on DIR Fee Reform Groups emphasize DIR fee reform’s power to reduce out-of-pocket drug costs and to reduce overall healthcare costs as a result of medication adherence and better health

2019-02-12T17:08:10+00:00Feb-12-19|Categories: Press Release|Tags: , , , , |

NACDS and the National Community Pharmacists Association (NCPA) today lauded 24 patient and consumer groups for advocating for pharmacy direct and indirect remuneration (DIR) fee reform.

NACDS Demonstrates Need for DIR Fee Reform in Comments to CMS Supports agency proposal to reduce patients’ out-of-pocket drug costs, reduce overall healthcare costs, improve patient health, and address drastically unfair reimbursement to pharmacies

2019-02-28T16:34:35+00:00Jan-25-19|Categories: Press Release|Tags: , , , , |

Based on insights from member pharmacies that serve as the front lines of healthcare delivery, the National Association of Chain Drug Stores (NACDS) has submitted extensive and thoroughly documented

Pharmacy Groups Praise CMS’ Progress on DIR Fee Reform to Lower Patients’ Out-of-Pocket Drug Costs

2018-11-27T17:12:16+00:00Nov-27-18|Categories: Press Release|Tags: , |

The National Community Pharmacists Association, the National Association of Chain Drug Stores, and the National Association of Specialty Pharmacy issued a statement regarding the Centers for Medicare & Medicaid Services’ release on Monday of the proposed rule titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."

House Sends NACDS-Backed “Gag Clause” Prohibition to President Legislation prevents restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance;NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs

2018-09-25T17:03:37+00:00Sep-25-18|Categories: Press Release|Tags: , , |

The legislation will prevent restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance. Meanwhile, NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs.

NACDS Addresses DIR Fees, Other “Access Agenda” Priorities in National Drug-Pricing Policy Discussion NACDS responds to request-for-information from HHS Secretary Azar for “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs”

2019-02-28T16:42:19+00:00Jul-18-18|Categories: Press Release|Tags: , , , , , , |

NACDS has submitted comments to Health and Human Services Secretary Alex Azar in response to the agency’s request-for-information on drug-pricing public policy issues.

Load More Posts